CSPG4 and cancer: More sophisticated mAb-based approaches, including chimeric anti-CSPG4 antibodies fused to super-antigens, bi- and tri-specific antibodies, or cytolytic fusion protein of CSPG4-specific single-chain antibody fragment genetically fused to microtubule-associated protein (MAP) tau, were also exploited [97–101], confirming the efficacy of the immune-targeting of CSPG4-positive cancer cells.